Network meta-analysis on the efficacy and safety of finerenone versus SGLT2 inhibitors on reducing new-onset of atrial fibrillation in patients with type 2 diabetes mellitus and chronic kidney disease

被引：0
作者：
Yaofu Zhang
Junheng Wang
Li Jiang
Tongxin Wang
Zhuang Li
Xiaozhe Fu
Weijun Huang
Yonghua Xiao
Shidong Wang
Jinxi Zhao
机构：
[1] Beijing University of Chinese Medicine,Dongzhimen Hospital
[2] Xiyuan Hospital,National Clinical Research Center for Chinese Medicine Cardiology
[3] China Academy of Chinese Medical Sciences,undefined
[4] Key Laboratory of Chinese Internal Medicine of Ministry of Education and Beijing,undefined
[5] Dongzhimen Hospital affiliated to Beijing University of Chinese Medicine,undefined
来源：
Diabetology & Metabolic Syndrome | / 14卷
关键词：
Atrial fibrillation; SGLT2 inhibitors; Finerenone; Type 2 diabetes mellitus; Chronic kidney disease;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
[31]   Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by diuretic use: A FIDELITY analysis [J].
Mentz, Robert J. ;
Anker, Stefan D. ;
Pitt, Bertram ;
Rossing, Peter ;
Ruilope, Luis M. ;
Gebel, Martin ;
Kolkhof, Peter ;
Lawatscheck, Robert ;
Rohwedder, Katja ;
Bakris, George L. ;
FIDELIO-DKD FIGARO-DKD Investigators .
EUROPEAN JOURNAL OF HEART FAILURE, 2025, 27 (05) :764-774
[32]   Effect of SGLT2 Inhibitors on Stroke and Atrial Fibrillation in Diabetic Kidney Disease Results From the CREDENCE Trial and Meta-Analysis [J].
Zhou, Zien ;
Jardine, Meg J. ;
Li, Qiang ;
Neuen, Brendon L. ;
Cannon, Christopher P. ;
de Zeeuw, Dick ;
Edwards, Robert ;
Levin, Adeera ;
Mahaffey, Kenneth W. ;
Perkovic, Vlado ;
Neal, Bruce ;
Lindley, Richard I. .
STROKE, 2021, 52 (05) :1545-1556
[33]   Comment on "The efficacy and safety of SGLT2 inhibitors in patients with non-diabetic chronic kidney disease" [J].
Chen, I. -Wen ;
Chang, Li-Chen ;
Hung, Kuo-Chuan .
INTERNATIONAL UROLOGY AND NEPHROLOGY, 2024, 56 (06) :2115-2116
[34]   Comment on “The efficacy and safety of SGLT2 inhibitors in patients with non-diabetic chronic kidney disease” [J].
I.-Wen Chen ;
Li-Chen Chang ;
Kuo-Chuan Hung .
International Urology and Nephrology, 2024, 56 :2115-2116
[35]   The cardiovascular outcomes of finerenone in patients with chronic kidney disease and type 2 diabetes: A meta-analysis of randomized clinical trials [J].
Abdelazeem, Basel ;
Elbadawy, Merihan A. ;
Awad, Ahmed K. ;
Kheiri, Babikir ;
Kunadi, Arvind .
INTRACTABLE & RARE DISEASES RESEARCH, 2022, 11 (01) :31-33
[36]   Finerenone efficacy in patients with chronic kidney disease, type 2 diabetes and atherosclerotic cardiovascular disease [J].
Filippatos, Gerasimos ;
Anker, Stefan D. ;
Pitt, Bertram ;
McGuire, Darren K. ;
Rossing, Peter ;
Ruilope, Luis M. ;
Butler, Javed ;
Jankowska, Ewa A. ;
Michos, Erin D. ;
Farmakis, Dimitrios ;
Farjat, Alfredo E. ;
Kolkhof, Peter ;
Scalise, Andrea ;
Joseph, Amer ;
Bakris, George L. ;
Agarwal, Rajiv .
EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY, 2022, 9 (01) :85-93
[37]   Comparison the effects of finerenone and SGLT2i on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus: A network meta-analysis [J].
Li, Xuefeng ;
Wu, Hongli ;
Peng, Huifang ;
Jiang, Hongwei .
FRONTIERS IN ENDOCRINOLOGY, 2022, 13
[38]   Association of SGLT2 Inhibitors With Risk of Atrial Fibrillation and Stroke in Patients With and Without Type 2 Diabetes: A Systemic Review and Meta-Analysis of Randomized Controlled Trials [J].
Zheng, Ru-Jie ;
Wang, Yue ;
Tang, Jun-Nan ;
Duan, Jie-Ying ;
Yuan, Ming-Yue ;
Zhang, Jin-Ying .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2022, 79 (02) :145-152
[39]   BP-lowering effects of SGLT-2 inhibitors and finerenone: an indirect comparison in patients with chronic kidney disease and type 2 diabetes [J].
Georgianos, Panagiotis I. ;
Kourtidou, Christodoula ;
Divani, Maria ;
Liakopoulos, Vassilios .
EXPERT OPINION ON PHARMACOTHERAPY, 2024, 25 (02) :127-130
[40]   Tumor risks of finerenone in patients with type 2 diabetes mellitus complicated with chronic kidney disease: a meta-analysis and systematic review of randomized controlled trials [J].
Du, Yue ;
Cao, Gui ;
Gu, Linlin ;
Chen, Yuehong ;
Liu, Jingyu .
FRONTIERS IN PHARMACOLOGY, 2024, 14
12345